Apixaban is primarily used as an anticoagulant to prevent blood clots in patients with conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. It is often prescribed to reduce the risk of stroke in individuals with non-valvular atrial fibrillation. Additionally, it is used for the prevention of venous thromboembolism in patients who have undergone hip or knee replacement surgery. The medication works by inhibiting Factor Xa, a key component in the blood clotting process, thereby reducing the likelihood of clot formation. It is typically administered orally and is favored for its predictable pharmacokinetics and lower risk of bleeding complications compared to older anticoagulants like warfarin.